CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 23 enrolled
Drug / intervention
BI 10773 +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01276288
NCT01276288Phase 1Completed
CompareCT.gov

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between 25 mg BI 10773 and 25 mg Hydrochlorothiazide or 5 mg Torasemide Under Steady State Conditions in Patients With Type 2 Diabetes Mellitus in an Open-label, Randomised, Cross-over Trial

Boehringer Ingelheim·interventional·Posted Jan 13, 2011·Updated Sep 3, 2014

In Brief

A Phase 1 clinical trial evaluating BI 10773, hydrochlorothiazide, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The primary objective of the study is to investigate the effect of BI 10773, hydrochlorothiazide and torasemide on changes in serum and urine electrolytes. Furthermore the pharmacodynamic and pharmacokinetic interactions between BI 10773 and diuretics should be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 13, 2011
Enrollment StartJan 1, 2011
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.5 years ago

Interventions

BI 10773drug

multiple oral doses

hydrochlorothiazidedrug

multiple oral doses

torasemidedrug

multiple oral doses

BI 10773drug

multiple oral doses

torasemidedrug

multiple oral doses

BI 10773drug

multiple oral doses

hydrochlorothiazidedrug

multiple oral doses